These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 23144856)

  • 1. A personalized BEST: characterization of latent clinical classes of nonischemic heart failure that predict outcomes and response to bucindolol.
    Kao DP; Wagner BD; Robertson AD; Bristow MR; Lowes BD
    PLoS One; 2012; 7(11):e48184. PubMed ID: 23144856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation.
    Kao DP; Davis G; Aleong R; O'Connor CM; Fiuzat M; Carson PE; Anand IS; Plehn JF; Gottlieb SS; Silver MA; Lindenfeld J; Miller AB; White M; Murphy GA; Sauer W; Bristow MR
    Eur J Heart Fail; 2013 Mar; 15(3):324-33. PubMed ID: 23223178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined HF Population: The GENETIC-AF Trial.
    Piccini JP; Abraham WT; Dufton C; Carroll IA; Healey JS; van Veldhuisen DJ; Sauer WH; Anand IS; White M; Wilton SB; Aleong R; Rienstra M; Krueger SK; Ayala-Paredes F; Khaykin Y; Merkely B; Miloradović V; Wranicz JK; Ilkhanoff L; Ziegler PD; Davis G; Emery LL; Marshall D; Kao DP; Bristow MR; Connolly SJ;
    JACC Heart Fail; 2019 Jul; 7(7):586-598. PubMed ID: 31042551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myocardial contractile reserve by dobutamine stress echocardiography predicts improvement in ejection fraction with beta-blockade in patients with heart failure: the Beta-Blocker Evaluation of Survival Trial (BEST).
    Eichhorn EJ; Grayburn PA; Mayer SA; St John Sutton M; Appleton C; Plehn J; Oh J; Greenberg B; DeMaria A; Frantz R; Krause-Steinrauf H
    Circulation; 2003 Nov; 108(19):2336-41. PubMed ID: 14597587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcome of carvedilol therapy in Japanese patients with nonischemic heart failure.
    Nagara K; Suzuki A; Shiga T; Hagiwara N
    Heart Vessels; 2020 Jul; 35(7):957-966. PubMed ID: 31970509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of outcomes and usefulness of carvedilol across a spectrum of left ventricular ejection fractions in patients with heart failure in clinical practice.
    Massie BM; Nelson JJ; Lukas MA; Greenberg B; Fowler MB; Gilbert EM; Abraham WT; Lottes SR; Franciosa JA;
    Am J Cardiol; 2007 May; 99(9):1263-8. PubMed ID: 17478155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heart Failure and Midrange Ejection Fraction: Implications of Recovered Ejection Fraction for Exercise Tolerance and Outcomes.
    Nadruz W; West E; Santos M; Skali H; Groarke JD; Forman DE; Shah AM
    Circ Heart Fail; 2016 Apr; 9(4):e002826. PubMed ID: 27009553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators.
    Bristow MR; O'Connell JB; Gilbert EM; French WJ; Leatherman G; Kantrowitz NE; Orie J; Smucker ML; Marshall G; Kelly P
    Circulation; 1994 Apr; 89(4):1632-42. PubMed ID: 7908610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenomics of Bucindolol in Atrial Fibrillation and Heart Failure.
    Parikh KS; Piccini JP
    Curr Heart Fail Rep; 2017 Dec; 14(6):529-535. PubMed ID: 28975475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Marked improvement in left ventricular ejection fraction during long-term beta-blockade in patients with chronic heart failure: clinical correlates and prognostic significance.
    Metra M; Nodari S; Parrinello G; Giubbini R; Manca C; Dei Cas L
    Am Heart J; 2003 Feb; 145(2):292-9. PubMed ID: 12595847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial.
    Cleland JG; Pennell DJ; Ray SG; Coats AJ; Macfarlane PW; Murray GD; Mule JD; Vered Z; Lahiri A;
    Lancet; 2003 Jul; 362(9377):14-21. PubMed ID: 12853194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenotyping Heart Failure According to the Longitudinal Ejection Fraction Change: Myocardial Strain, Predictors, and Outcomes.
    Park JJ; Mebazaa A; Hwang IC; Park JB; Park JH; Cho GY
    J Am Heart Assoc; 2020 Jun; 9(12):e015009. PubMed ID: 32519555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of beta-blockers in patients with stable chronic heart failure. Predictors of left ventricular ejection fraction improvement and impact on prognosis.
    de Groote P; Delour P; Mouquet F; Lamblin N; Dagorn J; Hennebert O; Le Tourneau T; Foucher-Hossein C; Verkindère C; Bauters C
    Am Heart J; 2007 Sep; 154(3):589-95. PubMed ID: 17719311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discharge treatment with angiotensin-converting enzyme inhibitor/angiotensin receptor blocker after a heart failure hospitalisation is associated with a better prognosis irrespective of left ventricular ejection fraction.
    Vicent L; Cinca J; Vazquez-García R; Gonzalez-Juanatey JR; Rivera M; Segovia J; Pascual-Figal D; Bover R; Worner F; Delgado-Jiménez J; Fernández-Avilés F; Martínez-Sellés M
    Intern Med J; 2019 Dec; 49(12):1505-1513. PubMed ID: 30887642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspirin impairs reverse myocardial remodeling in patients with heart failure treated with beta-blockers.
    Lindenfeld J; Robertson AD; Lowes BD; Bristow MR;
    J Am Coll Cardiol; 2001 Dec; 38(7):1950-6. PubMed ID: 11738299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COMPARE: comparison of the effects of carvedilol CR and carvedilol IR on left ventricular ejection fraction in patients with heart failure.
    Greenberg BH; Mehra M; Teerlink JR; Ordronneau P; McCollum D; Gilbert EM
    Am J Cardiol; 2006 Oct; 98(7A):53L-59L. PubMed ID: 17023233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics, Outcomes, and Treatment of Heart Failure With Improved Ejection Fraction.
    Park CS; Park JJ; Mebazaa A; Oh IY; Park HA; Cho HJ; Lee HY; Kim KH; Yoo BS; Kang SM; Baek SH; Jeon ES; Kim JJ; Cho MC; Chae SC; Oh BH; Choi DJ
    J Am Heart Assoc; 2019 Mar; 8(6):e011077. PubMed ID: 30845873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline and serial neurohormones in patients with congestive heart failure treated with and without bucindolol: results of the neurohumoral substudy of the Beta-Blocker Evaluation of Survival Study (BEST).
    Frantz RP; Lowes BD; Grayburn PA; White M; Krause-Steinrauf H; Krishnan V; Uyeda L; Burnett JC;
    J Card Fail; 2007 Aug; 13(6):437-44. PubMed ID: 17675057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between β-Blocker Use and Mortality/Morbidity in Patients With Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction and Advanced Chronic Kidney Disease.
    Fu EL; Uijl A; Dekker FW; Lund LH; Savarese G; Carrero JJ
    Circ Heart Fail; 2020 Nov; 13(11):e007180. PubMed ID: 33070637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of treatment with carvedilol vs metoprolol succinate and mortality in patients with heart failure.
    Pasternak B; Svanström H; Melbye M; Hviid A
    JAMA Intern Med; 2014 Oct; 174(10):1597-604. PubMed ID: 25173681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.